Mezigdomide: all 22 studies that test it
Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.
- A Study of Revumenib and Mezigdomide in People With LeukemiaRecruitingNCT07356154Phase 1/2
- Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AMLRecruitingNCT07355335Phase 1
- A Study of Teclistamab and Mezigdomide in People With Multiple MyelomaRecruitingNCT07105059Phase 1
- Mezigdomide and Talquetamab in Relapsed and Refractory Multiple MyelomaRecruitingNCT07032714Phase 1
- A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06988488Phase 1/2
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingNCT06892522Phase 1/2
- Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06645678Phase 1/2
- Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary DiseaseRecruitingNCT06627751Phase 2
- Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple MyelomaRecruitingNCT06048250Phase 1
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT05651932Phase 1
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingNCT05519085Phase 3
- A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal ImpairmentCompletedNCT06318676Phase 1
- A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT06163898Phase 1
- Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple MyelomaWithdrawnNCT06050512Phase 1/2
- Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted TherapiesActive, not recruitingNCT05981209Phase 1
- A Study of Mezigdomide in Healthy Participants and Participants With Hepatic ImpairmentCompletedNCT05707390Phase 1
- A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)Active, not recruitingNCT05552976Phase 3
- A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy ParticipantsCompletedNCT05389722Phase 1
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult ParticipantsCompletedNCT04839809Phase 1
- A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male ParticipantsCompletedNCT04560738Phase 1
- Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy SubjectsCompletedNCT04211545Phase 1
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy SubjectsCompletedNCT03803644Phase 1